To date, our antibodies are unique in discriminating native LL37 from cit-LL37 and the demonstration that they do not recognize ubiquitously expressed autoantigens, such as vimentin and enolase, suggests their use in autoimmune diseases, particularly in RA [29,30,31]. Here, VIM is linked to rheumatoid arthritis.